ClinicalTrials.gg
CompletedNCT01614470KONNECTIONUpdated Oct 29, 2014Results posted

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

A Phase 3 interventional study of Ivacaftor and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 12 sites in 3 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
58th of 84
39 · median 70
Started
2012
with 3 others
Phase 3
45 of 84
none open now
Registered
16th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 58th largest by enrollment, is one of 4 that started in 2012, is one of 45 in phase 3, and was the 16th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).

Read the detailed description

Ivacaftor is the first CFTR modulator to show an improvement in CFTR function and clinical benefit in subjects with CF. Results from Phase 3 studies (VX08-770-102 [Study 102] [NCT00909532] and VX08-770-103 [Study 103] [NCT00909727]) showed that ivacaftor is effective in the treatment of subjects with CF who have the G551D-CFTR mutation, as evidenced by sustained improvements in CFTR channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. Ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments.

Ivacaftor (Trade Name Kalydeco; 150 mg tablets) was initially approved in the United States for the treatment of CF in subjects 6 years of age and older who have a G551D mutation in the CFTR gene.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with confirmed diagnosis of CF
  • At least 1 allele of the following CFTR gating mutations: G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D
  • Percent predicted (FEV1) greater than or equal to (>=) 40 percent (%) predicted normal for age, sex, and height
  • 6 years of age or older
  • Minimum weight of 15 kilogram (kg) at screening
  • Females of must not be pregnant
  • Willing to comply with requirements

Exclusion criteria

Exclusion Criteria:

  • G551D-CFTR mutation on at least 1 allele
  • History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the subject
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of study drug
  • History of solid organ or hematological transplantation
  • History of alcohol, medication or illicit drug abuse within 1 year before the first dose of study drug
  • Ongoing participation in another therapeutic clinical study or prior participation in an drug study within 30 days before screening
  • Use of inhaled hypertonic saline treatment
  • Use of any inhibitors or inducers of cytochrome (CYP) P450 3A
  • Evidence of cataract or lens opacity at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Part 1: Ivacaftor First, Then Placebo

    Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.

    Drug: Ivacaftor · Drug: Placebo

  • Experimental
    Part 1: Placebo First, Then Ivacaftor

    Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.

    Drug: Ivacaftor · Drug: Placebo

  • Experimental
    Part 2: Ivacaftor

    Ivacaftor 150 mg tablet orally twice daily for 16 weeks.

    Drug: Ivacaftor

Interventions

  • 150 mg tablet, oral use, administered twice a day (q12h)

    Also known as: Kalydeco, VX-770

  • DrugPlacebo

    oral use, administered twice a day (q12h)

06

What researchers measure

Primary outcomes

  1. Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

    Time frame: Part 1: Baseline (pre-dose Day 1), Week 8

  2. Part 2: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through 24 Weeks of Treatment (Week 36 Visit)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Absolute change in percent predicted FEV1 over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2, as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

    Time frame: Baseline (pre-dose Week 12), Week 36

Secondary outcomes

  1. Part 1: Change From Baseline in Body Mass Index (BMI) at Week 8

    BMI was defined as weight in kilogram (kg) divided by height in meters\^2 (m\^2). Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

    Time frame: Part 1: Baseline (pre-dose Day 1), Week 8

  2. Part 2: Change From Baseline in Body Mass Index (BMI) at 24 Weeks of Treatment (Week 36 Visit)

    BMI was defined as weight in kg divided by height in m\^2. Change in BMI over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

    Time frame: Baseline (pre-dose Week 12), Week 36

  3. Part 1: Change From Baseline in Sweat Chloride Through Week 8

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

    Time frame: Part 1: Baseline (pre-dose Day 1), Week 8

  4. Part 2: Change From Baseline in Sweat Chloride Through 24 Weeks of Treatment (Week 36 Visit)

    Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Change in sweat chloride over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

    Time frame: Baseline (pre-dose Week 12), Week 36

  5. Part 1: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8

    The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

    Time frame: Part 1: Baseline (pre-dose Day 1), Week 8

  6. Part 2: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through 24 Weeks of Treatment (Week 36 Visit)

    The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Change in CFQ-R respiratory domain score over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

    Time frame: Baseline (pre-dose Week 12), Week 36

  7. Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.

    Time frame: Part 1: From signing of informed consent up to Week 20

  8. Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.

    Time frame: Part 2: Week 20 up to Week 40

07

Results

Posted Oct 29, 2014

Participant flow

Part 1: Treatment Period 1 (8 Weeks)
Participant flow — Part 1: Treatment Period 1 (8 Weeks)
MilestonePart 1: Ivacaftor First, Then PlaceboPart 1: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started20190
Completed18180
Not completed210
Withdrew: Lost to follow-up100
Withdrew: Need to extend washout period110
Part 1: Washout Period (4 to 8 Weeks)
Participant flow — Part 1: Washout Period (4 to 8 Weeks)
MilestonePart 1: Ivacaftor First, Then PlaceboPart 1: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started18180
Completed18180
Not completed000
Part 1: Treatment Period 2 (8 Weeks)
Participant flow — Part 1: Treatment Period 2 (8 Weeks)
MilestonePart 1: Ivacaftor First, Then PlaceboPart 1: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started18180
Completed18180
Not completed000
Part 2: Open-label Period (16 Weeks)
Participant flow — Part 2: Open-label Period (16 Weeks)
MilestonePart 1: Ivacaftor First, Then PlaceboPart 1: Placebo First, Then IvacaftorPart 2: Ivacaftor
Started0036
Completed0036
Not completed000

Outcome measures

PrimaryPart 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

Time frame:
Part 1: Baseline (pre-dose Day 1), Week 8
Reported as:
Mean · percent predicted of FEV1
Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8
percent predicted of FEV1Part 1: IvacaftorPart 1: Placebo
Baseline (n=38, 37)76.3659 ± 20.3345079.3361 ± 20.83991
Change Through Week 8 (n=37, 37)8.1308 ± 9.94676-5.8738 ± 7.23722
Statistical analysis
  • Part 1: Ivacaftor vs Part 1: Placebo · Mixed Models Analysis · p = <0.0001 · Least squares (ls) mean difference: 10.6780 · 95% CI 7.2559 to 14.1000
SecondaryPart 1: Change From Baseline in Body Mass Index (BMI) at Week 8

BMI was defined as weight in kilogram (kg) divided by height in meters\^2 (m\^2). Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

Time frame:
Part 1: Baseline (pre-dose Day 1), Week 8
Reported as:
Mean · kg/m^2
Part 1: Change From Baseline in Body Mass Index (BMI) at Week 8
kg/m^2Part 1: IvacaftorPart 1: Placebo
Baseline (n=38, 37)22.241 ± 5.188022.527 ± 4.9956
Change at Week 8 (n=37, 37)0.748 ± 0.57930.043 ± 0.6980
Statistical analysis
  • Part 1: Ivacaftor vs Part 1: Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 0.6624 · 95% CI 0.3366 to 0.9881
SecondaryPart 2: Change From Baseline in Body Mass Index (BMI) at 24 Weeks of Treatment (Week 36 Visit)

BMI was defined as weight in kg divided by height in m\^2. Change in BMI over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

Time frame:
Baseline (pre-dose Week 12), Week 36
Reported as:
Mean · kg/m^2
Part 2: Change From Baseline in Body Mass Index (BMI) at 24 Weeks of Treatment (Week 36 Visit)
kg/m^2Part 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor
Baseline22.222 ± 6.2919
Change at Week 361.263 ± 0.7588
SecondaryPart 1: Change From Baseline in Sweat Chloride Through Week 8

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

Time frame:
Part 1: Baseline (pre-dose Day 1), Week 8
Reported as:
Mean · millimole per liter (mmol/L)
Part 1: Change From Baseline in Sweat Chloride Through Week 8
millimole per liter (mmol/L)Part 1: IvacaftorPart 1: Placebo
Baseline (n=38, 37)93.37 ± 18.09994.23 ± 20.581
Change Through Week 8 (n=36, 36)-55.82 ± 24.890-5.63 ± 9.833
Statistical analysis
  • Part 1: Ivacaftor vs Part 1: Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -49.1667 · 95% CI -56.9527 to -41.3807
PrimaryPart 2: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through 24 Weeks of Treatment (Week 36 Visit)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male subjects 18 years and older and female subjects 16 years and older. The Wang standard was used for male subjects aged 6 to 17 years and for female subjects aged 6 to 15 years. Absolute change in percent predicted FEV1 over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2, as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

Time frame:
Baseline (pre-dose Week 12), Week 36
Reported as:
Mean · percent predicted of FEV1
Part 2: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through 24 Weeks of Treatment (Week 36 Visit)
percent predicted of FEV1Part 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor
Baseline74.8375 ± 19.36754
Change Through Week 3613.5307 ± 10.18174
SecondaryPart 2: Change From Baseline in Sweat Chloride Through 24 Weeks of Treatment (Week 36 Visit)

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Change in sweat chloride over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

Time frame:
Baseline (pre-dose Week 12), Week 36
Reported as:
Mean · mmol/L
Part 2: Change From Baseline in Sweat Chloride Through 24 Weeks of Treatment (Week 36 Visit)
mmol/LPart 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor
Baseline (n=18)92.03 ± 11.468
Change Through Week 36 (n=17)-59.24 ± 32.566
SecondaryPart 1: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8

The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during study Part 1.

Time frame:
Part 1: Baseline (pre-dose Day 1), Week 8
Reported as:
Mean · units on a scale
Part 1: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 8
units on a scalePart 1: IvacaftorPart 1: Placebo
Baseline (n=38, 37)70.61 ± 17.40974.55 ± 20.616
Change Through Week 8 (n=37, 37)12.31 ± 16.891-2.33 ± 20.648
Statistical analysis
  • Part 1: Ivacaftor vs Part 1: Placebo · Mixed Models Analysis · p = 0.0004 · Ls mean difference: 9.6105 · 95% CI 4.4874 to 14.7336
SecondaryPart 2: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through 24 Weeks of Treatment (Week 36 Visit)

The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Change in CFQ-R respiratory domain score over 24 weeks of ivacaftor treatment (from Week 12 \[Part 1: Treatment Period 2\] through Week 36 \[Part 2\]) was reported for subjects who received ivacaftor in Part 1: Treatment Period 2 as per planned analysis. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug during Part 1: Treatment Period 2.

Time frame:
Baseline (pre-dose Week 12), Week 36
Reported as:
Mean · units on a scale
Part 2: Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through 24 Weeks of Treatment (Week 36 Visit)
units on a scalePart 1 Treatment Period 2: Ivacaftor, Part 2: Ivacaftor
Baseline71.30 ± 19.526
Change Through Week 3611.42 ± 13.604
SecondaryPart 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.

Time frame:
Part 1: From signing of informed consent up to Week 20
Reported as:
Number · participants
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPart 1: IvacaftorPart 1: Placebo
AEs2831
SAEs47
SecondaryPart 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any adverse change from subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.

Time frame:
Part 2: Week 20 up to Week 40
Reported as:
Number · participants
Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPart 2: Ivacaftor
AEs30
SAEs3

Adverse events

Collected over Part 1: From signing of informed consent up to Week 20; Part 2: Week 20 up to Week 40. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Ivacaftor—4/38 (10.5%)27/38 (71.1%)
Part 1: Placebo—7/37 (18.9%)30/37 (81.1%)
Part 2: Ivacaftor—3/36 (8.3%)30/36 (83.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPart 1: IvacaftorPart 1: PlaceboPart 2: Ivacaftor
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/386/372/36
Distal intestinal obstruction syndromeGastrointestinal disorders0/380/371/36
DehydrationMetabolism and nutrition disorders0/380/371/36
ConvulsionNervous system disorders0/380/371/36
DizzinessNervous system disorders0/380/371/36
Appendiceal MucocoeleGastrointestinal disorders0/381/370/36
IntussusceptionGastrointestinal disorders0/381/370/36
Paranasal CystRespiratory, thoracic and mediastinal disorders0/381/370/36
PneumothoraxRespiratory, thoracic and mediastinal disorders0/381/370/36
Distal Ileal Obstruction SyndromeGastrointestinal disorders1/380/370/36
Most frequent other events
Showing 10 of 123
Most frequent other events
EventPart 1: IvacaftorPart 1: PlaceboPart 2: Ivacaftor
CoughRespiratory, thoracic and mediastinal disorders6/387/375/36
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations7/386/374/36
HeadacheNervous system disorders3/385/374/36
Abdominal painGastrointestinal disorders1/384/373/36
NauseaGastrointestinal disorders1/384/371/36
Upper respiratory tract infectionInfections and infestations1/382/373/36
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/383/373/36
AsthmaRespiratory, thoracic and mediastinal disorders0/381/373/36
Sputum increasedRespiratory, thoracic and mediastinal disorders3/383/372/36
RalesRespiratory, thoracic and mediastinal disorders1/383/371/36

Baseline characteristics

Full Analysis Set (FAS) was defined as all randomized subjects who received at least 1 dose of study drug (ivacaftor or placebo).

Age, Continuous
Age, Continuous(years)Part 1: Ivacaftor First, Then PlaceboPart 1: Placebo First, Then IvacaftorTotal
Mean23.8 ± 13.2521.7 ± 12.9222.8 ± 12.96
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Ivacaftor First, Then PlaceboPart 1: Placebo First, Then IvacaftorTotal
Female71017
Male13922
08

Study locations

12 sites
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Minneapolis, Minnesota, United States
  • St. Louis, Missouri, United States
  • Houston, Texas, United States
  • Leuven, Belgium
  • Lyon, France
  • Montpellier, France
  • Paris, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2012
First posted
Jun 8, 2012
Start
Jul 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 29, 2014
Last update
Oct 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01614470
Collaborators
Cystic Fibrosis Foundation
Responsible party
Sponsor
First posted
Jun 8, 2012
Start date
Jul 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 29, 2014
Last update
Oct 29, 2014

Study contacts

Christine De Boeck, MD, PhD
principal investigator · University of Leuven

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion